Jazz Pharmaceuticals plc (ETR:J7Z)
Germany · Delayed Price · Currency is EUR | Market Cap | 13.83B +111.8% |
| Revenue (ttm) | 4.03B +12.6% |
| Net Income | 823.44M |
| EPS | 12.81 |
| Shares Out | n/a |
| PE Ratio | 16.80 |
| Forward PE | 9.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13 |
| Open | 213.60 |
| Previous Close | 211.60 |
| Day's Range | 211.50 - 213.70 |
| 52-Week Range | 193.10 - 228.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic ... [Read more]
News
Jazz Pharmaceuticals price target raised to $337 from $315 at UBS
UBS raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $337 from $315 and keeps a Buy rating on the shares. Jazz’s post-GEA approval of Ziihera supports near- to…
Jazz Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026
Record Q2 revenue and double-digit growth across all brands highlight strong commercial execution. Ziihera's launch in GEA and expansion plans drive raised peak sales guidance, while new clinical programs and acquisitions strengthen rare disease leadership. AI and digital tools enhance patient identification and retention.
Jazz Pharmaceuticals price target raised to $271 from $270 at Barclays
Barclays raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $271 from $270 and keeps an Overweight rating on the shares after the FDA approved Ziihera and Tevimbra for…
Jazz Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Record Q2 revenue growth was driven by strong execution across all key brands, resilient performance from Xywav, and successful launches of Rylaze and ZEPZELCA. Ziihera's GEA launch is expected to be transformative, with a raised peak sales outlook and expansion into new indications. Continued innovation and disciplined business development underpin future growth.
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fa...
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backbone therapy in first-line GEA Longer follow up of Ziihera plus tislelizumab and chemotherapy shows i...
Jazz Pharmaceuticals price target raised to $299 from $277 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $299 from $277 and keeps an Outperform rating on the shares. The firm sees potential…
Jazz Pharmaceuticals prices upsized $1.1B offering of exchangeable senior notes
Jazz Pharmaceuticals (JAZZ) announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 in a private offering by Jazz Investments I Limited, its wholl...
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior no...
Jazz Pharmaceuticals price target raised to $281 from $264 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $281 from $264 and keeps a Buy rating on the shares. The firm cites the company’s…
Jazz Pharmaceuticals price target raised to $322 from $283 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $322 from $283 and keeps an Overweight rating on the shares. After the FDA approved both Ziihera-containing regimens…
Jazz Pharmaceuticals price target raised to $310 from $292 at Needham
Needham raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $310 from $292 and keeps a Buy rating on the shares. The firm cites the company’s investor call yesterday…
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), inte...
Jazz Pharmaceuticals price target raised to $300 from $287 at Deutsche Bank
Deutsche Bank analyst David Hoang raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $300 from $287 and keeps a Buy rating on the shares. The firm cites the…
Jazz Pharmaceuticals Transcript: FDA announcement
FDA approved Ziihera as the first bispecific HER2-targeted antibody with a PD-1 inhibitor and chemotherapy for first-line HER2-positive metastatic GEA, showing unprecedented survival benefits. The launch leverages established infrastructure, with peak sales projected at $3B-$5B and ongoing expansion into additional tumor types.
Jazz Pharmaceuticals Press release: FDA announcement
Jazz Pharmaceuticals issued a press release on August 25, 2026, disclosing material business information to investors.
Jazz Pharmaceuticals Slides: FDA announcement
Jazz Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.
Jazz Pharmaceuticals announces FDA approval of two Ziihera-containing regimens
Jazz Pharmaceuticals (JAZZ) announced that the U.S. FDA approved two Ziihera-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive g...
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front...
Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for $820 million. Deal centers around Actio's lead drug for KCNT+ epilepsy, ABS-1230.
Jazz Pharmaceuticals price target raised to $283 from $280 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $283 from $280 and keeps an Overweight rating on the shares after the company announced it will acquire…
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio
Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at up to $1.32 billion, adding an experimental treatment for a rare inherited form of epilepsy that...
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront
07:30 EDT Jazz Pharmaceuticals (JAZZ) to acquire Actio Biosciences for $820M upfront
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront
Jazz Pharmaceuticals (JAZZ) and Actio Biosciences announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820M upfront and up to $500...
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction i...